TuHURA Biosciences Stock (NASDAQ:HURA)

Ownership Financials Chart

Previous Close

$2.29

52W Range

$1.80 - $7.20

50D Avg

$2.57

200D Avg

$3.12

Market Cap

$115.17M

Avg Vol (3M)

$391.30K

Beta

-0.10

Div Yield

-

HURA Company Profile

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Feb 22, 2013

Website

HURA Performance

HURA Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-29.76M	$-9.93M	$-7.25M
Net Income	$-29.32M	$-9.37M	$-7.02M
EBITDA	$-29.12M	$-9.56M	$-6.01M
Basic EPS	$-0.12	$-202.39	$-0.17
Diluted EPS	$-0.12	$-202.39	$-0.17

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
SPRO	Spero Therapeutics, Inc.
AGEN	Agenus Inc.
SEER	Seer, Inc.
INO	Inovio Pharmaceuticals, Inc.
VTGN	VistaGen Therapeutics, Inc.
CGTX	Cognition Therapeutics, Inc.
ONCY	Oncolytics Biotech Inc.
CNTX	Context Therapeutics Inc.
OVID	Ovid Therapeutics Inc.